Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ketoconazole Therapy and Exfoliative Erythroderma

Ketoconazole Therapy and Exfoliative Erythroderma Abstract To the Editor.— Ketoconazole is a newly approved oral agent effective against fungal pathogens.1 In vitro studies suggest that the drug impairs the synthesis of ergosterol, a vital component of fungal cell membranes. This process is unimportant in the metabolism of mammalian cells. Studies, involving more than 1,200 patients, have shown that the drug may have important toxic effects on the liver that, occasionally, can be fatal. Nausea and vomiting have been reported in 3% of the patients. According to the manufacturer, Janssen Pharmaceutica, New Brunswick, NJ, to date, no rashes have been reported from the drug, but pruritus is a complaint in 1.5% of the patients. We describe an exfoliative erythroderma occurring in a patient receiving ketoconazole therapy. Report of a Case.— A 48-year-old man who had a history of chronic renal failure was first seen by us for evaluation of an exfoliative erythroderma.He was in good References 1. Graybill JR, Herndon JH, Kniker WT, et al: Ketoconazole treatment of chronic mucocutaneous candidiasis . Arch Dermatol 1980;116:1137-1141.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Ketoconazole Therapy and Exfoliative Erythroderma

Loading next page...
 
/lp/american-medical-association/ketoconazole-therapy-and-exfoliative-erythroderma-CJ5trHRou4

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1983.01650260005004
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— Ketoconazole is a newly approved oral agent effective against fungal pathogens.1 In vitro studies suggest that the drug impairs the synthesis of ergosterol, a vital component of fungal cell membranes. This process is unimportant in the metabolism of mammalian cells. Studies, involving more than 1,200 patients, have shown that the drug may have important toxic effects on the liver that, occasionally, can be fatal. Nausea and vomiting have been reported in 3% of the patients. According to the manufacturer, Janssen Pharmaceutica, New Brunswick, NJ, to date, no rashes have been reported from the drug, but pruritus is a complaint in 1.5% of the patients. We describe an exfoliative erythroderma occurring in a patient receiving ketoconazole therapy. Report of a Case.— A 48-year-old man who had a history of chronic renal failure was first seen by us for evaluation of an exfoliative erythroderma.He was in good References 1. Graybill JR, Herndon JH, Kniker WT, et al: Ketoconazole treatment of chronic mucocutaneous candidiasis . Arch Dermatol 1980;116:1137-1141.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Feb 1, 1983

There are no references for this article.